Joseph Stringer

Stock Analyst at Needham

(0)
# 3340
Out of 5,240 analysts
289
Total ratings
32.50%
Success rate
1.66%
Average return
23 Stocks
Name Action Price Target Current % Upside Ratings Updated
Alnylam Pharmaceutic...
Reiterates: Buy
320 320
240.92 32.82% 17 Jan 13, 2025
Phathom Pharmaceutic...
Reiterates: Buy
28 28
6.78 312.98% 47 Jan 10, 2025
Stoke Therapeutics
Maintains: Buy
22 22
8.65 154.34% 19 Jan 8, 2025
Lexicon Pharmaceutic...
Reiterates: Hold
n/a
n/a n/a 10 Dec 23, 2024
Vertex Pharmaceutica...
Reiterates: Hold
n/a
n/a n/a 3 Dec 20, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
60 60
32.68 83.6% 17 Dec 20, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
19 19
10.21 86.09% 15 Nov 20, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
16 16
4.54 252.42% 17 Nov 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
60 60
26.99 122.3% 15 Nov 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Hold
n/a
n/a n/a 8 Nov 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Hold
n/a
n/a n/a 3 Nov 7, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
55 64
53.94 18.65% 18 Nov 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
140 140
78.15 79.14% 13 Nov 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
85 60
27.69 116.68% 19 Nov 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
23 23
1.5 1433.33% 16 Nov 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
25 25
20.86 19.85% 8 Aug 14, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
38 38
11.24 238.08% 14 Aug 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
n/a
n/a n/a 16 Jun 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
37
16.89 119.06% 5 Jan 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
n/a
n/a n/a 5 May 23, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
42 32
n/a n/a 1 May 13, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
n/a
n/a n/a 1 Dec 13, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
32 18
8.53 111.02% 2 Aug 24, 2021